Disclosure of contingent liabilities [line items] Disclosure of contingent liabilities [line items] Anthony Mancini Anthony Mancini [Member] Represents information pertaining to Anthony Mancini. Disclosure of geographical areas [line items] Disclosure of geographical areas [line items] Committee Fees Key Management Personnel Compensation, Committee Fees The amount of committee fees paid by the key management personnel. Elizabeth O’Farrell Elizabeth O'Farrell [Member] Represents information pertaining to Elizabeth O'Farrell. Interest coverage ratio Interest Coverage Ratio Interest Coverage Ratio Investment in tangible assets Purchase of property, plant and equipment, classified as investing activities Capital Structure, Financial Risk And Related Items [Abstract] Capital Structure, Financial Risk And Related Items Wages and salaries Wages and salaries Entity File Number Entity File Number Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination [line items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Acquisition and Integration Related Charges Description Of Accounting Policy For Acquisition And Integration Related Charges [Policy Text Block] Description Of Accounting Policy For Acquisition And Integration Related Charges Schedule of segment disclosures in the financial statements as the group's business activities. Schedule Of Segment Disclosures In Financial Statements [Table Text Block] Tabular disclosure for segment disclosures in the financial statements as the group's business activities. Levels of fair value hierarchy [domain] Levels of fair value hierarchy [domain] Anthony Pagano Anthony Pagano [Member] Represents information pertaining to Anthony Pagano. Other payables excluding provisions Other Payables Excluding Provisions [Member] This member stands for other payables. 2027 Later than two years and not later than three years [member] Cash and cash equivalents include: Cash and cash equivalents [abstract] Deferred tax liability Deferred tax liabilities recognised as of acquisition date Other current and deferred tax adjustments Other tax effects for reconciliation between accounting profit and tax expense (income) Net financial items Finance income (cost) Fair value measurement Description of accounting policy for fair value measurement [text block] Disclosure of detailed information about borrowings [table] Disclosure of detailed information about borrowings [table] Schedule of treasury shares Disclosure of treasury shares [text block] Intangible assets and goodwill at beginning of period Intangible assets and goodwill at end of period Intangible assets and goodwill Statement of changes in equity [line items] Statement of changes in equity [line items] Privately held equity securities Privately Held Equity Securities [member] This member stands for privately held equity securities. Interest elements of lease payments Adjustments For Interest On Lease Payments Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities. Number of operating segment Number Of Operating Segment1 Number Of Operating Segment1 Disclosure of geographical areas [table] Disclosure of geographical areas [table] Additions for the year Acquisitions through business combinations, intangible assets and goodwill Financial assets measured at fair value through profit or loss Financial assets at fair value through profit or loss, category [member] Third authorization Stock Repurchase Third Authorization [Member] Represents the third authorization under the share repurchase arrangement by the board of directors. Effect of exchange rate adjustment Increase (decrease) through net exchange differences, intangible assets and goodwill Statement of financial position [abstract] Other interest expense Interest expense on other financial liabilities Cover [Abstract] USD portfolio USD Portfolio [Member] This member stands for USD Portfolio. Maximum Maximum [Member] Disclosure of reclassifications or changes in presentation Disclosure of reclassifications or changes in presentation [text block] Maximum number of product concepts for which cost-plus margin approach was utilized Maximum Number of Product Concepts for Which Cost Plus Margin Approach Was Utilized Represents the maximum number of product concepts for which a cost-plus margin approach was utilized for co-development activities. Transactions with owners: Transactions With Owners [Line Items] n/a Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Total Trade receivables Net increase (decrease) of unrecognized deferred tax assets for the year Tax Effect Of Adjustment To Unrecognized Deferred Tax Assets The amount of tax effect of adjustment to unrecognized deferred tax assets. Entity Shell Company Entity Shell Company Share premium Share premium Cash flows from financing activities: Cash flows from (used in) financing activities [abstract] Period two Period Two [Member] Period Two Other Other Royalty Products [Member] This member stands for other royalty product. Proportion of share capital on shares used for funding RSU program (in %) Percentage Of Share Capital On Sale Of Treasury Shares Percentage of proportion of share capital on shares used for funding RSU program. Opening balance before adjustment, cumulative effect at date of initial application [member] Opening balance before adjustment, cumulative effect at date of initial application [member] Total comprehensive income Comprehensive income Comprehensive income Excess Cash Flow Prepayment Scenario [Domain] Excess Cash Flow Prepayment Scenario [Domain] Excess Cash Flow Prepayment Scenario [Domain] Exercise of warrants Share Capital Exercise Of Warrants Share Capital Exercise Of Warrants. Cash flow projection, period (in years) Cash Flow Projection, Forecast Period Cash Flow Projection, Forecast Period Revenue (as a percent) Percentage Of Revenue Percentage of revenue. Work in progress Current work in progress Basis of Presentation Disclosure of basis of preparation of financial statements [text block] Merus US Inc. Merus US Inc. [Member] Merus US Inc. Document Fiscal Period Focus Document Fiscal Period Focus Total assets Total assets Assets Litigation Case [Domain] Litigation Case [Domain] Mijke Zachariasse Mijke Zachariasse [Member] Represents information pertaining to Mijke Zachariasse. Corporate Tax Description of accounting policy for income tax [text block] Parent Company Parent Company [Member] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Number of other equity instruments outstanding in share-based payment arrangement Business Combinations Description of accounting policy for business combinations [text block] Total tax effect Current tax expense (income) and adjustments for current tax of prior periods Goodwill Description of accounting policy for goodwill [text block] Credit risk Credit risk [member] Staff Costs Staff Cost [Abstract] No definition available. Trading Symbol Trading Symbol Expected life of warrants (in years) Weighted Average, Expected Life, Warrants Granted The expected life of share options granted. Weighted average exercise price of warrants exercisable in money (in DKK per share) Weighted Average Exercise Price Of Warrants Exercisable In Money Exercise price per share or per unit of warrants exercisable in money during the period. Increase (decrease) in current other payables Increase (Decrease) In Current Other Payables Increase (Decrease) In Current Other Payables Revenue Upfront payment recognized Revenue Entity Address, City or Town Entity Address, City or Town Birgitte Stephensen Birgitte Stephensen [Member] Represents information pertaining to Birgitte Stephensen. Financial expenses: Financial expenses: [Line Items] na Share capital Issued capital [member] Cumulative effect at date of initial application [axis] Cumulative effect at date of initial application [axis] Royalties expiration term after the first sale of each licensed product Collaborations Agreement, Royalties Expiration Term After First Sale of Each Licensed Product Represents the royalties expiration term after the first sale of each licensed product in such country. Cash paid for outstanding shares Cash Transferred For Outstanding Shares The fair value, at acquisition date, of cash transferred for outstanding shares as consideration in a business combination. Performance obligations [domain] Performance obligations [domain] Chugai Patent Infringement Complaint Chugai Patent Infringement Complaint [Member] Chugai Patent Infringement Complaint Schedule of executive compensation Disclosure of information about key management personnel [text block] Selling, general and administrative expenses Selling, general and administrative expense [member] Entity Emerging Growth Company Entity Emerging Growth Company ProfoundBio US Co. Profoundbio Us Co [Member] This member stands for ProfoundBio, US Co. Acquisition of assets, net of cash acquired Purchase of other long-term assets, classified as investing activities Other Payables Description of accounting policy for trade and other payables [text block] Kingdom of Denmark bonds and treasury bills Kingdom Of Denmark Bonds And Treasury Bills [Member] This member stands for Kingdom of Denmark bonds and treasury bills. Transfers between the classes Increase (decrease) through transfers, property, plant and equipment Warrants reissued (in shares) Number Of Warrants Reissued Number of warrants reissued. Other Other Marketable Securities [Member] This member stands for other marketable securities. First authorization Stock Repurchase First Authorization [Member] Represents the first authorization under the share repurchase arrangement by the board of directors. Disposals for the year Disposals, property, plant and equipment Tax at the Danish corporation tax rate of 22% for all periods Tax expense (income) at applicable tax rate Board of Directors Total Board of Directors [Member] Represents information pertaining to board of directors. Exercise price of outstanding share options (in DKK per share) Exercise price of outstanding share options Assets under construction Construction in progress [member] Technology platform intangible asset Technology Platform Technology-based intangible assets [member] ASSETS Assets [abstract] Receivables excluding prepayments Receivables Excluding Prepayments [Member] This member stands for Receivables Excluding Prepayments. Fair value changes Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, assets Increase (decrease) in interest income (in percentage) Percentage of Increase (Decrease) in Interest Income Percentage of increase in interest income. Treasury stock, shares outstanding (in shares) Treasury Stock, Shares Outstanding Number of shares of treasury stock outstanding. External credit grades [axis] External credit grades [axis] Schedule of portfolio of marketable securities Schedule Of Portfolio Of Marketable Securities [Table Text Block] Tabular disclosure of portfolio of marketable securities. Danish mortgage-backed securities Danish Mortgage-Backed Securities [Member] This member stands for Danish mortgage-backed securities. Other payables Current other payables Other current payables Entity Address, Postal Zip Code Entity Address, Postal Zip Code Merus Merus [Member] Merus Right-of-use assets Presentation of leases for lessee [abstract] Cash and cash equivalents Cash acquired Cash and cash equivalents Cash and cash equivalents recognised as of acquisition date Document Information [Line Items] Document Information [Line Items] Net leverage ratio Net Leverage Ratio Net Leverage Ratio ProfoundBio Inc. Profoundbio Inc [Member] This member stands for ProfoundBio, Inc Revenue Description of accounting policy for recognition of revenue [text block] Weighted average exercise price of warrant exercised (in DKK per share) Weighted Average Exercise Price Of Warrants Exercised Exercise price per share or per unit of warrants exercised during the period. Weighted average exercise price of warrants cancelled (in DKK per share) Weighted Average Exercise Price Of Warrants Forfeited Exercise price per share or per unit of warrants cancelled during the period. Foreign exchange rate loss Foreign exchange rate loss Foreign exchange loss Number of products were in active clinical development Number of Products in Active Clinical Development The number of DuoBody-based products created under this collaboration were in active clinical development. Exercise price warrants granted (in DKK per share) Exercise Price, Warrants Granted The exercise price of share warrants granted. Disclosure Of Detailed Information About Changes in Presentation Currency [Table] Disclosure Of Detailed Information About Changes in Presentation Currency [Table] Disclosure Of Detailed Information About Changes in Presentation Currency Bank deposits Cash Depreciation and impairment loss recognised in profit or loss Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss Cash flows from investing activities: Cash flows from (used in) investing activities [abstract] Adjustments for share-based instruments, dilution (in shares) Dilutive effect of convertible instruments on weighted average number of ordinary shares Warrants issued (in shares) Number Of Warrants Issued Number of warrants issued. Share-based compensation expenses Increase (decrease) through share-based payment transactions, equity Acquired IPR&D IPR&D intangible asset In Process Research and Development. [Member] In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process. Lease liabilities Lease liabilities [abstract] Other payables Non-current other payables Other non-current payables Total non-current assets Non-current assets Results for the Year [Abstract] No definition available. Michael Kavanagh Michael Kavanagh [Member] Michael Kavanagh Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Foreign exchange gain (loss) Foreign exchange gain (loss) Warrants exercised Proceeds from exercise of warrants Classes of property, plant and equipment [domain] Classes of property, plant and equipment [domain] Gain (loss) on marketable securities, net Gain (Loss) On Marketable Securities, Net Amount of gain (loss) on marketable securities, net. Selling, General and Administrative Expenses Description Of Accounting Policy For Selling General And Administrative Expenses [Policy Text Block] Description Of Accounting Policy For Selling General And Administrative Expenses Audit-related fees Auditor's Remuneration For Audit Related Services The amount of fees paid or payable to the entity's auditors for audit related services. Entity Address, Country Entity Address, Country Disclosure Of Receivables [Line Items] Disclosure Of Receivables [Line Items] Line item of receivables. EUR Euro Member Countries, Euro Reimbursement revenue Reimbursement Revenue [Member] This member stands for reimbursement income. Other liabilities Other Liabilities Recognised As Of Acquisition Date Other Liabilities Recognised As Of Acquisition Date Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Exchange rate adjustments Effect of exchange rate changes on cash and cash equivalents Integration related charges Integration Related Charges Related To Acquisitions Integration Related Charges Related To Acquisitions Foreign Currency Description of accounting policy for foreign currency translation [text block] Impairment losses Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Types of revenues [axis] Types of Revenues [Axis] The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table. Intangible assets Intangible Assets, Temporary Difference [Member] This member stands for intangible assets with respect to temporary difference. Document Annual Report Document Annual Report Contract Liabilities Non-current contract liabilities Non-current contract liabilities Disclosure of detailed information about financial instruments [table] Disclosure of detailed information about financial instruments [table] Geographical areas [domain] Geographical areas [domain] Novartis (Arzaerra/Ofatumumab) Agreements With Novartis [Member] This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab). Receivables Current receivables Trade and other current receivables Capital Structure, Financial Risk and Related Items Disclosure of financial risk management [text block] Entity Interactive Data Current Entity Interactive Data Current Number of shares per RSU (in shares) Share Based Arrangement, Number Of Shares Per RSU Number of shares credited for one share of RSU owned by the holder under the share based payment arrangements. Reclass Increase (decrease) due to changes in accounting policy [member] Disclosure of maturity analysis of operating lease payments [table] Disclosure of maturity analysis of operating lease payments [table] Consideration paid (received) Consideration paid (received) Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] Financial expenses Total financial expenses Finance costs Research and development expenses Research And Development Expenses of Acquiree The amount of research and development expenses of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. Corporate taxes paid Adjustments for income tax expense Acquisitions through business combinations Acquisitions through business combinations, property, plant and equipment Consideration received Contract Liabilities, Consideration Received Contract Liabilities, Consideration Received Disclosure of credit risk exposure [table] Disclosure of credit risk exposure [table] Balance at beginning of period (in shares) Balance at end of period (in shares) Number Of Warrants Outstanding The number of warrants held as of the balance sheet date. Other liabilities Other liabilities Net of non-taxable income over non-deductible expenses Non Deductible Expenses Non-Taxable Income And Other Permanent Differences, Net The amount of non-deductible expenses/non-taxable income and other permanent differences, net Entity Central Index Key Entity Central Index Key Schedule of inventories Schedule Of Inventory, Current. [Table Text Block] Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. Presentation currency change Increase (decrease) due to changes in accounting policy required by IFRSs [member] Excluding net product Sales Excluding Net Product Sales [Member] Excluding Net product Sales [member] Unsecured revolving credit facility Unsecured Revolving, Credit Facility [Member] This member stands for unsecured revolving credit facility. Financial Covenant Period [Axis] Financial Covenant Period [Axis] Financial Covenant Test Milestone revenue Milestone Revenue [Member] This member stands for revenue from milestone payments. Acquisition and integration related charges Acquisition and integration related charges Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Percentage of increase (decrease) in gain (loss) of marketable securities Percentage Of Increase (Decrease) In Gain (Loss) Of Marketable Securities Percentage of decrease in gain of marketable securities compared to prior period. Net Profit Profit (loss) of combined entity as if combination occurred at beginning of period Deferred Tax Description of accounting policy for deferred income tax [text block] SHAREHOLDERS' EQUITY AND LIABILITIES Equity and liabilities [abstract] Reconciliation of changes in property, plant and equipment [abstract] Reconciliation of changes in property, plant and equipment [abstract] Entity Filer Category Entity Filer Category Rayne Waller Rayne Waller [Member] This member stands for Rayne Waller. Average rate Average foreign exchange rate Additions for the year Additions other than through business combinations, property, plant and equipment Operating profit Profit (loss) from operating activities Accumulated depreciation on disposals Depreciation On Disposal, Property Plant And Equipment The amount of depreciation of on disposal property, plant and equipment. Audit fees Auditor's remuneration for audit services Estimated impact for net profit before tax due to increase or decrease In exchange rate Estimated Impact of Net Profit Before Tax Due to Increase or Decrease In Exchange Rate The estimated impact for net profit before tax due to increase or decrease In exchange rate. Entity Address, Address Line One Entity Address, Address Line One Cost (USD million) Cost Of Treasury Shares [Abstract] No definition available. Receivables related to collaboration agreements Collaboration Agreements, Receivables The amount of receivables under collaboration agreement. Exercisable at year end (in shares) Number Of Warrants Exercisable Number of warrants exercisable at the end of year. Statement of cash flows [abstract] Disclosure of financial assets [table] Disclosure of financial assets [table] Tahamtan Ahmadi Tahamtan Ahmadi [Member] This member stands for Tahamtan Ahmadi. Total value of bank deposits Bank Deposits Including Short Term Marketable Securities The value of bank deposits including short-term marketable securities. Genmab K.K. Genmab K.k. [Member] This member stands for Genmab K.K. Defined contribution plans Post-employment benefit expense in profit or loss, defined benefit plans Number of investigational medicine Number Of Investigational Medicine Number Of Investigational Medicine Marketable securities were invested (as a percent) Percentage of Marketable Securities Invested Percentage of marketable securities invested. Denmark DENMARK Royalties by Product [Axis] Royalties by Product [Axis] Information by royalties by product. Schedule of level 3 reconciliation of assets Disclosure Of Fair Value Measurement Of Assets, Level 3 Reconciliation [Table Text Block] Tabular disclosure of level 3 reconciliation of assets measured at fair value. Other investments Investments accounted for using equity method Fund investments Investment funds [member] Disclosure of fair value measurement of assets [line items] Disclosure of fair value measurement of assets [line items] Warrant vesting period Warrant Vesting Period Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Amortization expense Amortisation expense Other comprehensive income: Other comprehensive income [abstract] Additions for the year Additions, Intangible Assets And Goodwill Additions, Intangible Assets And Goodwill Classes of share capital [domain] Classes of share capital [domain] Adjustment to deferred tax Adjustments for deferred tax of prior periods Summary of terms and conditions of share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [text block] China CHINA Prepayments Prepayments Classes of contingent liabilities [domain] Classes of contingent liabilities [domain] Other investments bought Purchase of interests in investments accounted for using equity method Financial income Total financial income Finance income Classes of financial liabilities [axis] Classes of financial liabilities [axis] Classes of financial liabilities [domain] Classes of financial liabilities [domain] Document Shell Company Report Document Shell Company Report Additions to right-of-use assets Additions to right-of-use assets Acquisition of business, net of cash acquired Cash used for acquisition of asset Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Expired (in shares) Number Of Warrants Expired Number of warrants expired. Average number of FTE Average number of employees AbbVie AbbVie [Member] This member stands for collaboration arrangement with Abbvie. Other non-current assets Other Non-Current Assets Recognised As Of Acquisition Date The amount recognised as of the acquisition date for other non-current assets acquired in a business combination. Future minimum payments under our leases Undiscounted operating lease payments to be received Total lease liabilities Lease liabilities Number of votes Number Of Votes Number of votes. Research and development expenses Research And Development [Member] Research And Development Audit Information [Abstract] Audit Information Proportion of reduction in share capital (in %) Percentage Of Reduction In Share Capital Percentage Of Reduction In Share Capital Genmab (Beijing) Co., Ltd. Genmab (Beijing ) Co., Ltd. [Member] Minimum Minimum [Member] Cost and profit sharing ratio Collaborations Agreement, Cost And Profit Sharing Ratio Represents the cost and profit sharing ratio. Summary of RSUs activity Disclosure of number and weighted average exercise prices of other equity instruments [text block] Acquisitions Purchases, fair value measurement, assets Receivables Description of accounting policy for trade and other receivables [text block] Disclosure of maturity analysis of operating lease payments [abstract] Disclosure of maturity analysis of operating lease payments [abstract] Share capital Share capital, at beginning of period Share capital, at end of period Issued capital Gross unrecognized tax loss carryforwards Unused tax losses for which no deferred tax asset recognised Collaborative Arrangement and Arrangement Other Than Collaborative [Domain] Collaborative Arrangement and Arrangement Other Than Collaborative [Domain] Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. Categories of financial assets [axis] Categories of financial assets [axis] Number of shares, at beginning of period Number of shares, at end of period Number of shares outstanding Current stated Current Stated After Changes In Accounting Policy [Member] Current Stated After Changes In Accounting Policy Amount of provision recorded Other provisions Executive Management Total Executive Management [Member] Represents information pertaining to executive management. Financial liabilities Financial liabilities Other temporary differences Other temporary differences [member] Loss on other investments, net Loss on other investments, net Losses On Other Investments, Net Losses On Other Investments, Net Corporate tax Total tax for the period in the income statement Corporate tax expense Tax expense (income) Number of clinical research program Number Of Clinical Research Program Number Of Clinical Research Program Types of revenues [member] Types of Revenues [Member] This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used. Non-current contract liabilities Non-Current Contract Liabilities Recognised As of Acquisition Date Non-Current Contract Liabilities Recognised As of Acquisition Date Short term contractual obligations Short Term Contractual Obligations The amount of short term contractual obligations primarily related to research and development activities. Disclosure of maturity analysis of operating lease payments Disclosure of maturity analysis of operating lease payments [line items] Disclosure of detailed information about exchange rates Disclosure Of Detailed Information About Exchange Rates Explanatory [Table Text Block] Disclosure Of Detailed Information About Exchange Rates Explanatory Document Transition Report Document Transition Report Receivables Trade and other receivables Financial Covenant Period [Domain] Financial Covenant Period [Domain] Financial Covenant Test [Domain] Exercise price (in DKK per share) Weighted Average Exercise Price, Warrants Granted The weighted average exercise price of warrants granted. Cash flows from operating activities: Cash flows from (used in) operating activities [abstract] March 2017 - February 2021 GMAB Warrants Granted From March 2017 Until February 2021 [Member] Represents GMAB warrants granted from March2017 until February2021 member. Selling, general and administrative expenses Selling, general and administrative expense Document Period End Date Document Period End Date Upfront payment Proceeds From Non Refundable Upfront Payment Proceeds From Non Refundable Upfront Payment Disclosure of classes of share capital [line items] Disclosure of classes of share capital [line items] Exchange rate adjustment Increase (decrease) through net exchange differences, right-of-use assets Maturity [axis] Maturity [axis] Shares used for funding RSU program Sale or issue of treasury shares Asset Acquisition [Axis] Asset Acquisition. [Axis] Asset Acquisition. Gain on marketable securities Gains on Marketable Securities The gains on marketable securities. Goodwill Goodwill Number of delivery license programs Number of Delivery Licenses Represents the number of delivery license programs. Total tax for the period in shareholders' equity Tax expense (benefit) on items recognized directly in equity Current and deferred tax relating to items credited (charged) directly to equity Document Type Document Type Share-based compensation Employee benefits expense Expense from share-based payment transactions with employees Classes of financial assets [axis] Classes of financial assets [axis] Classification of categories of financial assets and liabilities Description of accounting policy for financial instruments at fair value through profit or loss [text block] Net increase (decrease) of unrecognized deferred tax assets for the year Adjustments For Unrecognized Deferred Tax Assets The amount of adjustment to unrecognized deferred tax assets. Profit or loss [abstract] Profit or loss [abstract] Contract liabilities Current contract liabilities Current contract liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Weighted average Black-Scholes fair value per warrant granted (in DKK per share) Weighted Average Exercise Price Of Fair Value Of Warrants Exercise price per share or per unit of fair value of warrants during the period. Revenue Revenue of combined entity as if combination occurred at beginning of period Classes of assets [axis] Classes of assets [axis] Percentage of discover research and development cost responsible by the entity Discover Research and Development Cost Responsibility Percent The percentage of discover research and development cost responsible by the entity. Number of business unit Number of Business Unit Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. Accounts payable Trade payables 2029 Later than four years and not later than five years [member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table] Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. Types of share-based payment arrangements [domain] Types of share-based payment arrangements [domain] Cash paid for Genmab directly attributable acquisition related costs Cash Transferred Related To Legal, Advisory And Other Acquisition Costs Cash Transferred Related To Legal, Advisory And Other Acquisition Costs Schedule of maturity profile of our marketable securities Disclosure Of Maturity Profile Of Our Marketable Securities [Table Text Block] Tabular disclosure of maturity profile of our marketable securities. Range [axis] Range [axis] Currently stated [member] Currently stated [member] Components of equity [axis] Components of equity [axis] Exchange rate adjustment Contract Liabilities, Exchange Rate Adjustment Contract Liabilities, Exchange Rate Adjustment Schedule of Inventories [Table] Schedule of Inventories [Table] Schedule disclosing information related to inventories. Restricted Stock Units (RSU) Restricted share units [member] Jan van de Winkel Jan Van De Winkel [Member] Represents information pertaining to Jan van de Winkel. Martin Schultz Martin Schultz [Member] Represents information pertaining to Martin Schultz. Net profit before tax Net profit before tax Net profit before tax Profit (loss) before tax Termination compensation period due to change in control Number of Period, Termination Severance Payment, Change in Control The period for which the termination severance pay the entity obliged to pay in the event of termination due to change in control. Accrued interest expense, borrowings Accrued Interest Expense, Borrowings Accrued Interest Expense, Borrowings Additions from asset acquisition Contract Liabilities, Additions From Assets Acquisitions Contract Liabilities, Additions From Assets Acquisitions Pension obligations Defined Contribution Plans, Pension Obligation The amount of pension obligation under defined contribution plan recognised. Proportion of share capital, at beginning of period (in %) Proportion of share capital, at end of period (in %) Percentage of share capital repurchased Percentage Of Share Capital Repurchased Percentage of share capital repurchased. Genmab Holding II B.V. Genmab Holding II B.V. [Member] Genmab Holding II B.V. Categories of related parties [domain] Categories of related parties [domain] Cost of product sales Staff Costs Included In Cost Of Product Sales The amount of staff cost included in cost of product sales. Statements of Cash Flows Description of accounting policy for cash flows [text block] Period three Period Three [Member] Period Three Performance obligations satisfied over time Performance obligations satisfied over time [member] Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [table] Total fair value of warrants granted Weighted Average Fair Value Of Warrants Granted Weighted average fair value of warrants granted. Depreciation Adjustments for depreciation expense Auditor Location Auditor Location Acquired in Business Combinations Increase (decrease) through business combinations, deferred tax liability (asset) Share Reduction Share capital reduction Share capital reduction Reduction of issued capital Interest received Interest received, classified as operating activities Second authorization Stock Repurchase Second Authorization [Member] Represents the second authorization under the share repurchase arrangement by the board of directors. Weighted average number of shares outstanding (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Schedule of other investments Schedule Of Other Investments [Table Text Block] Tabular disclosure of other Investments. Board of Directors And Executive Management [Member] Board of Directors And Executive Management [Member] Represents information pertaining to board of directors and executive management. Publicly traded equity securities Trading equity securities [member] Maximum credit exposure to receivables Maximum Exposure To Credit Risk Of Receivables The maximum exposure to the credit risk of receivables. Impairment of goodwill Impairment loss recognised in profit or loss, goodwill Roche Roche [Member] This member stands for collaboration arrangement with Roche. Financial guarantees Contingent liability for guarantees [member] Takahiro Hamatani Takahiro Hamatani [Member] Represents information pertaining to Takahiro Hamatani4. Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Other reserves Other reserves Defined contribution plans Share-Based Compensation Expenses Key management personnel compensation, share-based payment Borrowings Borrowings Schedule of total marketable securities by currency Disclosure Of Marketable Securities By Currency [Table Text Block] Tabular disclosure of marketable securities in foreign currency. Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Tax losses and credits carried forward Tax Losses And Credits Carried Forward, Temporary Difference [Member] Tax Losses And Credits Carried Forward, Temporary Difference Shares used for funding RSU program (in shares) Shares Used For Funding RSU Program Number of treasury shares sold. Short-term marketable securities Short-term investments, classified as cash equivalents Marketable securities Marketable Securities [Member] This member stands for marketable securities . Professional fees related to acquisition Professional Fees Related To Acquisitions Professional Fees Related To Acquisitions Genmab UK Ltd Genmab UK Ltd [Member] Genmab UK Ltd Base Board Fee Basic Board Fee The amount of expense relating to basic board fee. Net cash provided by (used in) financing activities Financing activities Cash flows from (used in) financing activities Number of performance obligations Number of Performance Obligations Represents the number of performance obligations. Revenue recognized during the year Contract Liabilities, Revenue Recognized During Period The amount of revenue that was recognized during the year from contract liability. Cash payment related to the portion of awards with future vesting conditions Cash Transferred for Outstanding Equity Awards for Settlement of Non-Vested Awards The fair value, at acquisition date, of cash transferred for outstanding equity awards for settlement related to the portion of awards with future vesting conditions, and therefore attributable to post-combination services as consideration in a business combination. Basic and Diluted Net Profit Per Share Description of accounting policy for earnings per share [text block] Deferred revenue Deferred Revenue, Temporary Differences [Member] This member stands for deferred revenue. Collaborations, License Agreements and Collaborative Agreements Description Of Accounting Policy For Collaborations, License Agreements And Collaborative Agreements [Policy Text Block] Description Of Accounting Policy For Collaborations, License Agreements And Collaborative Agreements Accumulated amortization and impairment Accumulated depreciation, amortisation and impairment [member] Entity Current Reporting Status Entity Current Reporting Status Shares used for funding RSU program Cost Of Treasury Shares Used For Funding Program, At Cost Cost of treasury shares used for funding RSU program. 1 – 3 years Later than one year and not later than three years [member] Schedule of components of the deferred tax asset Disclosure of deferred taxes [text block] Statement of changes in equity [table] Statement of changes in equity [table] Japan JAPAN AbbVie Rina-S Trade Secret Complaint AbbVie Rina-S Trade Secret Complaint [Member] AbbVie Rina-S Trade Secret Complaint DKK portfolio DKK Portfolio [Member] This member stands for DKK Portfolio. Purchase of treasury shares Purchase of Treasury Shares, At cost Value of treasury shares purchased. Period one Period One [Member] First Upfront payment Upfront Milestone Payment Received The amount of cash in flow from upfront milestone payments. Other current liabilities Other Current Liabilities Recognised As Of Acquisition Date The amount recognised as of the acquisition date for other current liabilities acquired in a business combination. Borrowings Current Current borrowings and current portion of non-current borrowings Cost of product sales Cost of sales Credit facility, maximum borrowing capacity Line Of Credit Facility, Maximum Borrowing Capacity1 Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Classes of assets [domain] Classes of assets [domain] Current Fiscal Year End Date Current Fiscal Year End Date UK government bonds and treasury bills UK Government Bonds And Treasury Bills [Member] This member stands for UK government bonds and treasury bills. Bottom of range Bottom of range [member] Categories of related parties [axis] Categories of related parties [axis] Financial liabilities measured at amortized cost Financial liabilities at amortised cost, category [member] Disclosure of detailed information about borrowings [line items] Disclosure of detailed information about borrowings [line items] Net profit Net profit Profit (loss) Financial assets Fair value at beginning of period Fair value at end of period Financial assets Ownership and votes (Percentage) Proportion Of Ownership Interest And Voting Rights In Subsidiary The proportion of ownership interest and voting rights in a subsidiary attributable to the entity Total non-current liabilities Non-current liabilities Property and equipment Property, plant and equipment recognised as of acquisition date Closing rate Closing foreign exchange rate Number of patents Number of Patents On Which the Case Filed Represents the number of patents on which the case is filed. Licenses and patents Non-current assets recognised as of acquisition date Document Registration Statement Document Registration Statement Number of shares at beginning of period Number of shares at end of period Number of shares issued Depreciation charge for the year Depreciation, right-of-use assets Temporary difference, unused tax losses and unused tax credits [domain] Temporary difference, unused tax losses and unused tax credits [domain] Marketable securities Market value Marketable Securities, Current. Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Retained earnings Retained earnings [member] Cash payment related to the portion of awards with future vesting conditions Payments For Post Combination Equity Awards The cash outflow for payment of post combination equity awards. Christopher Cozic Christopher Cozic [Member] Represents information pertaining to Christopher Cozic. 2026 Later than one year and not later than two years [member] Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Leases Description of accounting policy for leases [text block] Disclosure of rating of agencies for marketable securities Disclosure Of Rating Of Agencies For Marketable Securities [Table Text Block] Disclosure Of Rating Of Agencies For Marketable Securities Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Business Contact Business Contact [Member] GBP United Kingdom, Pounds Increase (decrease) in interest income Increase (Decrease) In Interest Income The amount of increase in interest income driven by higher effective interest rates in the U.S., Europe and Denmark for the respective periods. Corporate bonds Corporate Bonds [Member] This member stands for corporate bonds. Number of approved products jointly commercialized by collaboration partner Number Of Approved Products Jointly Commercialized With Collaboration Number of approved products jointly commercialized by collaboration partner. External credit grades [domain] External credit grades [domain] Categories of financial assets [domain] Categories of financial assets [domain] Carrying amount [member] Carrying amount [member] Comprehensive income [abstract] Comprehensive income [abstract] Disclosure Of Receivables [Table] Disclosure Of Receivables [Table] Schedule of information related to receivables. Changes in equity [abstract] Share capital Changes in equity [abstract] Wages and salaries Key management personnel compensation, short-term employee benefits Netherlands NETHERLANDS Security Exchange Name Security Exchange Name Transferred (in shares) Number Of Instruments Other Equity Instruments, Warrants, Transferred Number of warrants Transferred. Other Disclosures [Abstract] Other Disclosures [Abstract] No definition. Former member of Board of Directors, Executive Management and Employees Former Member of Board of Directors, Executive Management and Employees [Member] Represents information pertaining to former member of board of directors and employees . Term Loan A (Secured) Term Loan A (Secured) [Member] Term Loan A (Secured) Operating Assets and Liabilities Operating Assets And Liabilities [Text Block] The entire disclosure for operating assets and liabilities. Reduction in share capital Cancellation of treasury shares Rolf Hoffmann Rolf Hoffmann [Member] Represents information pertaining to Rolf Hoffmann. Right-of-use assets Balance at January 1 Balance at December 31 Right-of-use assets Shareholdings By Board Of Directors And Executive Management [Line items] Collaborations and Licenses Shareholdings By Board Of Directors And Executive Management [Line items] Na Contact Personnel Name Contact Personnel Name Purchase of treasury shares Purchase of treasury shares Purchase of treasury shares Purchase of treasury shares Cost of Product Sales Description Of Accounting Policy For Cost Of Product Sales [Policy Text Block] Description Of Accounting Policy For Cost Of Product Sales Unsecured Notes Senior Unsecured Notes [Member] Senior Unsecured Notes US government bonds and treasury bills US Government Bonds And Treasury Bills [Member] This member stands for US government bonds and treasury bills. Number of additional lawsuits Number Of Additional Lawsuits Number Of Additional Lawsuits Cash payment to holders of outstanding equity awards for settlement of such vested and non-vested awards Cash Transferred For Outstanding Equity Awards For Settlement Of Vested And Non-Vested Awards The fair value, at acquisition date, of cash transferred for outstanding equity awards for settlement of vested and non-vested awards as consideration in a business combination. Amounts which may be re-classified to the income statement: Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Contract liabilities at January 1 Contract liabilities at December 31 Contract liabilities Disclosure of reclassifications or changes in presentation [line items] Disclosure of reclassifications or changes in presentation [line items] Restricted cash balances for funds held in escrow Current restricted cash and cash equivalents ProfoundBio Limited Profound Limited [Member] This member stands for Profound Limited. Statistical Measurement [Domain] Statistical Measurement [Domain] Antidilutive shares (in shares) Number of potential ordinary shares that are antidilutive in period presented Schedule of finance income and expenses Disclosure Of Finance Income (Expenses) [Table Text Block] Disclosure Of Finance Income (Expenses) Cash and cash equivalents Cash And Cash Equivalents. [Member] Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Translation reserves Reserve of exchange differences on translation [member] Share-based instruments Share-Based Instruments, Temporary Differences [Member] This member stands for Share-Based Instruments. Total costs and operating expenses Operating expense Estimated useful life of intangibles (in years) Useful life measured as period of time, intangible assets other than goodwill Withholding taxes on behalf of employees on net settled RSUs Decrease (increase) through tax on share-based payment transactions, equity Classes of share capital [axis] Classes of share capital [axis] Disclosure of key financial risk areas Disclosure Of Key Financial Risk Areas [Table Text Block] Disclosure Of Key Financial Risk Areas Number of new patents Number of New Patents On Which the Case Filed Number Of Granted Patents Number of shares authorized (in shares) Number of shares authorised Total shareholders' equity Balance at beginning of period Balance at end of period Total shareholders' equity Equity Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Property and equipment Cost at beginning of period Cost at end of period Property, plant and equipment Other receivables Other receivables Number of approved products commercialized by third parties Number Of Approved Products Commercialized By Third Parties Number of approved products commercialized by third parties. Genmab Germany GmbH Genmab Germany GmbH [Member] Genmab Germany GmbH Weighted average number of shares excl. treasury shares (in shares) Average Number Of Ordinary Shares Excluding Treasury Shares Outstanding The number of ordinary shares excluding shares outstanding. Total impact on financial position on termination of services Impact On Financial Position Termination of Services Total impact on financial position on termination of services Research and Development Expenses and Projects Description of accounting policy for research and development expense [text block] Royalty obligation expiration term after first sale of product Collaborations Agreement, Royalty Obligation Expiration Term After First Sale Of Product Term from first sale of the product after which obligation to pay royalties under the agreement will expire. Exchange differences on translation of foreign operations Other comprehensive income, before tax, exchange differences on translation of foreign operations Level 1 Level 1 of fair value hierarchy [member] Gilead Sciences, Inc Gilead Gilead Sciences, Inc [Member] Gilead Sciences, Inc Schedule of cash outflow for leases Disclosure Of Cash Outflow For Leases [Table Text Block] Tabular disclosure of cash outflow for leases Government grants related to research and development expenses Expenses On Government Grants The amount of expenses incurred on government grants. Disclosure of detailed information about property, plant and equipment [line items] Depreciation and impairment included in the income statement as follows: Disclosure of detailed information about property, plant and equipment [line items] Equipment, furniture and fixtures Equipment, Furniture and Fixtures [Member] This member stand for Equipment, furniture and fixtures. Percentage of change in share capital - warrants exercised Percentage Of Share Capital Attributed To Exercise Of Warrants Percentage of share capital attributed by exercise of warrants which increase the share capital. Level 2 Level 2 of fair value hierarchy [member] Fair value per warrant on grant date (in DKK per share) Weighted Average Fair Value Per Warrant On Grant Date The weighted average fair value per warrant on grant date. Reconciliation of changes in intangible assets and goodwill [abstract] Reconciliation of changes in intangible assets and goodwill [abstract] Percentage of possible increase or decrease in exchange rate Percentage Of Possible Increase (Decrease) In Exchange rate Percentage of possible increase or decrease in exchange rate. Weighted average exercise price of warrant granted (in DKK per share) Weighted Average Exercise Price Of Warrants Granted Exercise price per share or per unit of warrants granted during the period. DKK Denmark, Kroner Shareholdings By Board of Director and Executive Management [Line Items] Shareholdings By Board of Director and Executive Management [Line Items] na Net deferred tax asset/(liability) at the beginning of the year Net deferred tax asset/(liability) at the end of the year Deferred tax liability (asset) Financial expenses: Financial Expenses [Abstract] Financial Expenses Total current liabilities Current liabilities Collaboration revenue Collaboration Revenue [Member] This member stands for collaboration revenue. ADR ADR [Member] Transfer to level 3 Transfers into Level 3 of fair value hierarchy, assets Inventories Total inventories Current inventories Document Accounting Standard Document Accounting Standard Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Weighted average exercise price of warrants expired (in DKK per share) Weighted Average Exercise Price Of Warrants Expired Exercise price per share or per unit of warrants expired during the period. Other current assets Other Current Assets Recognised As Of Acquisition Date The amount recognised as of the acquisition date for other current assets acquired in a business combination. Share-Based Instruments Description of accounting policy for share-based payment transactions [text block] Genmab Finance LLC. Genmab Finance LLC [Member] Genmab Finance LLC Statement of changes in equity [abstract] Retained earnings Retained earnings Measurement [domain] Measurement [domain] Schedule of details of acquisition Disclosure of detailed information about business combination [text block] Commitments and Contingencies [Abstract] Commitments and Contingencies [Abstract] na Staff cost liabilities Provisions for employee benefits Research and development expenses Staff Costs Included In Research And Development Expenses The amount of staff cost included in research and development expenses. Maximum credit exposure Maximum exposure to credit risk Schedule of contract liabilities Disclosure of deferred income [text block] Disclosure of detailed information about financial instruments [line items] Disclosure of detailed information about financial instruments [line items] Gain on other investments, net Gains On Other Investments, Net Gains On Other Investments, Net Granted (in shares) Number of other equity instruments granted in share-based payment arrangement Types of risks [domain] Types of risks [domain] Receivables Adjustments for decrease (increase) in trade and other receivables Legal Entity [Axis] Legal Entity [Axis] Subsidiaries [axis] Subsidiaries [axis] Interest paid Interest paid, classified as operating activities Geographical [Domain] Geographical [Domain] Weighted average exercise price of warrants exercisable (in DKK per share) Weighted Average Exercise Price Of Warrants Exercisable Exercise price per share or per unit of warrants exercisable during the period. Granted (in shares) Number Of Warrants Granted During Period The number of warrants granted during period. Geographical Areas Description of accounting policy for segment reporting [text block] Share Repurchase, percentage of share capital authorized Share Repurchase, Percentage of Share Capital Authorized Share Repurchase, Percentage of Share Capital Authorized Geographical areas [axis] Geographical areas [axis] Financial income Adjustments for finance income Merus B.V. Merus N.V. Merus B.V. [Member] Merus B.V. Performance obligations satisfied at point in time Performance obligations satisfied at point in time [member] Expected stock price volatility Weighted Average Expected Volatility, Warrants Granted The expected volatility of the share price used to calculate the fair value of warrants granted. Lease liabilities Non-current Non-current lease liabilities Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amount of seeking an award Amount Of Seeking An Award In Second Arbitration Represents the amount of seeking an award in this second arbitration. Other intangible assets Intangible assets other than goodwill Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Disclosure of fair value measurement of assets [table] Disclosure of fair value measurement of assets [table] Greg Mueller Greg Mueller [Member] Greg Mueller Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash and cash equivalents at the end of the period Cash and cash equivalents Financial income: Financial Income: [Line Items] na Marketable securities sold Proceeds from sales of investments other than investments accounted for using equity method Document Information [Table] Document Information [Table] Net product Sales Net Product Sales [Member] This member stands for net product sales Ratio of sharing pre tax profits Ratio of Sharing The Pre Tax Profits The ratio of sharing pre tax profits during the period. Schedule of borrowings Disclosure of detailed information about borrowings [text block] Total shareholders' equity and liabilities Equity and liabilities United States UNITED STATES Payment of withholding taxes on behalf of employees on net settled RSUs Payment Of Withholding Taxes On Behalf Of Employees On Net Settled RSUs The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs). Judith Klimovsky Judith Klimovsky [Member] Represents information pertaining to Judith Klimovsky. Business combinations [axis] Business combinations [axis] Secured Notes Senior Secured Notes [Member] Senior Secured Notes Business combinations [domain] Business combinations [domain] Cash for equity compensation attributable to pre-modification of equity awards Cash for equity compensation attributable to pre-combination service Cash Transferred For Outstanding Equity Awards For Settlement Of Vested Awards The fair value, at acquisition date, of cash transferred for outstanding equity awards for settlement of vested awards where the vesting period was completed as consideration in a business combination. Interest receivables Interest receivable Borrowings Long-term borrowings [member] Remaining useful life, projection (in years) Remaining Useful Life Measured As Period Of Time, Intangible Assets Other Than Goodwill Remaining Useful Life Measured As Period Of Time, Intangible Assets Other Than Goodwill Weighted average exercise price of warrants at beginning (in DKK per share) Weighted average exercise price of warrants at ending (in DKK per share) Weighted Average Exercise Price Of Warrants Outstanding Weighted average exercise price of warrants outstanding. City Area Code City Area Code Unrecognized tax losses Tax Benefit Arising From Previously Unrecognized Deferred Tax Assets The amount of benefit arising from a previously unrecognized deferred tax assets now recognized. Genmab Holding B.V. Genmab Holding B.v. [Member] This member stands for Genmab Holding B.V. USD United States of America, Dollars Disclosure of fair value of financial instruments Disclosure of fair value of financial instruments [text block] Expected useful lives of assets Useful life measured as period of time, property, plant and equipment Categories of financial liabilities [domain] Categories of financial liabilities [domain] Share price (in DKK per share) Weighted Average Share Price, Warrants Granted The weighted average price used as input to the option pricing model to calculate the fair value of warrants granted. More than 5 years 2030+ Later than five years [member] Other Other Collaboration Partners [Member] This member stands for collaborative arrangement with other collaboration partners. Other Benefits Key Management Personnel Compensation, Other Benefits The amount of compensation to key management personnel in the form of other benefits. New royalty term entitled as mentioned in declaration New Royalty Obligation Term, From The Date of First Commercial Sale of Product Represents the new royalty term entitled from the date of DARZALEX FASPRO's first commercial sale as mentioned in declaration in second arbitration. Classes of financial assets [domain] Classes of financial assets [domain] Basis of Presentation [Abstract] Basis of Presentation [Abstract] No definition available. Impairment losses for the year Impairment loss recognised in profit or loss, intangible assets and goodwill Level 3 Level 3 of fair value hierarchy [member] Level 3 of fair value hierarchy [member] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Management's Judgements and Estimates under IFRS Disclosure of accounting judgements and estimates [text block] Cash flows from operating activities before financial items Cash Flow From (Used In) Operating Activities Before Financial Items The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items. Goodwill Goodwill recognised as of acquisition date Corporate tax receivable Corporate Tax Receivable Corporate Tax Receivable Disclosure of classes of share capital [table] Disclosure of classes of share capital [table] Auditor Name Auditor Name Increase (decrease) in gain (loss) of marketable securities Increase (Decrease) In Gain (Loss) Of Marketable Securities Amount of decrease in gain of marketable securities compared to prior period. Asset Acquisition [Domain] Asset Acquisition. [Domain] Asset Acquisition. Number of candidates Business Combination, Number of Candidates in Clinical Development, Rights Received Represents the number of candidates in clinical development for which received the rights. Shareholdings By The Board Of Directors And Executive Management [Table] Shareholdings By The Board Of Directors And Executive Management [Table] Schedule disclosing information relating to shareholdings by the board of directors and executive management. Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Schedules of receivables Disclosure of trade and other receivables [text block] Goodwill Goodwill [member] Deferred tax assets including intangible assets Deferred Tax Assets Including Intangible Assets Deferred Tax Assets Including Intangible Assets Transaction price (in dollars per share) Transaction Price Per Share Transaction Price Per Share Percentage of marketable securities Percentage Of Marketable Securities The percentage of marketable securities. Contractually entitled to receive payments related to clinical development and commercial success Receivable Amount Related to Clinical Development and Commercial Success Represents the contractually entitled to receive payments related to clinical development and commercial success. Ratio of share of profits before income taxes Ratio of Share of Profits before Income Taxes The ratio of share of profits before income taxes. Net cash provided by operating activities Operating activities Cash flows from (used in) operating activities Finished goods Current finished goods Weighted average fair value per RSU granted (in DKK per share) Weighted Average Fair Value Of Other Equity Instruments Granted In Share Based Payment Arrangement The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement. Forfeited (in shares) Number of other equity instruments forfeited in share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Liabilities related to collaboration agreements Collaboration Agreements, Liabilities The amount of liabilities under collaboration agreement. Entity [Domain] Entity [Domain] Weighted average number of treasury shares (in shares) Average Number Of Treasury Shares Outstanding The number of treasury shares outstanding. Document Fiscal Year Focus Document Fiscal Year Focus Janssen Janssen [Member] This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab & DuoBody). Tax on items recognized directly in equity Decrease (Increase) Though Tax On Items Recognized Directly In Equity Decrease (Increase) Though Tax On Items Recognized Directly In Equity Adjustment for non-cash transactions Adjustments to reconcile profit (loss) [abstract] Number of period, termination severance payment Number of Period, Termination Severance Payment The period for which the termination severance pay the entity obliged to pay in the event of termination. Reconciliation of Contract Liabilities [Roll Forward] Reconciliation of Contract Liabilities [Roll Forward] Reconciliation of Contract Liabilities ProfoundBio ProfoundBio [Member] This member stands for ProfoundBio. Brad Bailey Brad Bailey [Member] This member stands for Brad Bailey. European government bonds and treasury bills European Government Bonds And Treasury Bills [Member] This member stands for European government bonds and treasury bills. Base Salary Key Management Personnel Compensation, Base Salary The amount of compensation to key management personnel in the form of base salary. Leasehold improvements Leasehold improvements [member] New Accounting Policies and Disclosures Effective in 2026 or Later Disclosure of expected impact of initial application of new standards or interpretations [text block] Genmab France SAS Genmab France SAS [Member] Genmab France SAS Operating Assets and Liabilities [Abstract] No definition available. Foreign exchange rate gain Foreign exchange gain Total Key management personnel compensation Expected dividend yield Weighted Average Expected Dividend Yield, Warrants Granted The percentage of an expected dividend used to calculate the fair value of warrants granted. Disclosure of credit risk exposure [line items] Disclosure of credit risk exposure [line items] Ordinary shares Ordinary shares [member] Trade receivables related to product sales Current trade receivables Summary of fees to auditors Disclosure of auditors' remuneration [text block] Schedule of profit per share Disclosure of earnings per share [text block] Excess cash flow threshold Borrowings, Excess Cash Flow, Threshold Borrowings, Excess Cash Flow, Threshold Gross carrying value Gross Gross carrying amount [member] Applicable tax rate (%) Applicable tax rate Fees to Auditors Appointed at the Annual General Meeting Auditor's remuneration [abstract] Other payables Adjustments for increase (decrease) in other liabilities Financial expense Adjustments for finance costs Local Phone Number Local Phone Number Within 1 year 2025 Not later than one year [member] Summary of remuneration of the Board of Directors and Executive Management Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block] Royalties Royalties [Member] This member stands for revenue form royalties. Genmab (Suzhou) Co., Ltd. Genmab (Suzhou) Co., Ltd [Member] Genmab (Suzhou) Co., Ltd Licenses and patents Licenses and Patents Licenses and Patents [Member] This member stands for a class of intangible assets representing licenses and patents. Intangible asset Identifiable intangible assets recognised as of acquisition date Total Auditor's remuneration Cost, at beginning of period Cost at end of period Treasury Shares, At Cost Cost of treasury shares. Contract transaction price Contract Transaction Price The identified transaction price under the contract. Borrowings Non-Current Non-current portion of non-current borrowings Effect of exchange rate adjustment Adjustments For Foreign Exchange Rates Adjustments For Foreign Exchange Rates Inventories Adjustments for decrease (increase) in inventories Disclosure of financial assets [line items] Disclosure of financial assets [line items] Property, plant and equipment Property, plant and equipment [member] Property and Equipment Description of accounting policy for property, plant and equipment [text block] Consideration transferred, acquisition-date fair value Total consideration Consideration transferred, acquisition-date fair value Proceeds from issuance of borrowings Proceeds from borrowings, classified as financing activities Schedule of Inventories [Line Items] Schedule of Inventories [Line Items] Line item of inventories. Principal elements of lease payments Payments of lease liabilities, classified as financing activities Entity Voluntary Filers Entity Voluntary Filers Percentage of ownership interest in subsidiary Proportion of ownership interest in subsidiary Royalties by Product [Domain] Royalties by Product [Domain] Information by royalties by product. Entity Registrant Name Entity Registrant Name Raw materials Current raw materials Basic net profit per share (in dollars per share) Earnings per share - basic (in DKK and US Dollars per share) Basic earnings (loss) per share Financial income: Financial Income [Abstract] Financial Income Weighted average remaining contractual life (in years) Weighted Average Remaining Contractual Life Of Outstanding Warrants Weighted average remaining contractual life of outstanding warrants. Measurement [axis] Measurement [axis] Weighted average number of shares, diluted (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Novartis Novartis [Member] This member stands for collaborative arrangement with Novartis. Schedule of fair value of each warrant granted Disclosure of Valuation Assumptions for Warrants Granted [Table Text Block] Tabular disclosure of fair value of each warrant granted. Classes of intangible assets other than goodwill [domain] Classes of intangible assets other than goodwill [domain] Share-based compensation expense Adjustments for share-based payments Total Other payables Schedule of warrants issued and reissued during the period Disclosure Of Warrants Issued And Warrants Reissued Activity [Table Text Block] Tabular disclosure of Warrants issued and reissued during the period. Paolo Paoletti Paolo Paoletti [Member] Represents information pertaining to Paolo Paoletti. Schedule of financial assets and liabilities, fair value measurement Disclosure of offsetting of financial assets and financial liabilities [text block] Number of shares Number Of Shares [Abstract] No definition available. Classes of intangible assets and goodwill [axis] Classes of intangible assets and goodwill [axis] Exercisable warrants in the money at year end (in shares) Number Of Warrants Exercisable In The Money Number of exercisable warrants in the money at year end. Schedule of intangible assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Employees Employees [Member] Represents information pertaining to Employees. All Currencies [Domain] All Currencies [Domain] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Current contract liabilities Current Contract Liabilities Recognised As Of Acquisition Date Current Contract Liabilities Recognised As Of Acquisition Date Asset Acquisitions Description Of Accounting Policy For Assets Acquisitions [Policy Text Block] Description Of Accounting Policy For Assets Acquisitions Disclosure of reclassifications or changes in presentation [table] Disclosure of reclassifications or changes in presentation [table] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Disclosure of detailed information about changes in presentation currency Disclosure Of Detailed Information About Changes in Presentation Currency [Table Text Block] Disclosure Of Detailed Information About Changes in Presentation Currency Pernille Erenbjerg Pernille Erenbjerg [Member] Represents information pertaining to Pernille Erenbjerg. Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Cash outflow for lease payments Cash outflow for leases Other social security costs Social security contributions Litigation Case [Axis] Litigation Case [Axis] Transfers (in shares) Number Of Warrants Transferred Number of warrants Transferred. Amortization Adjustments for amortisation expense Auditor Firm ID Auditor Firm ID Share-based compensation expenses Key management personnel compensation, post-employment benefits Purchase of treasury shares Payments To Acquire Treasury Shares The cash outflow to acquire treasury shares. Share premium Share premium [member] Schedule of revenue by type, collaboration partner, and product under agreements. Disclosure of disaggregation of revenue from contracts with customers [text block] Financial assets pledged as collateral for liabilities or contingent liabilities Financial assets pledged as collateral for liabilities or contingent liabilities Development Regulatory and Sales Milestone Development Regulatory and Sales Milestone [Member] Represents the information pertaining to development, regulatory and sales milestone. Remuneration of the Board of Directors and Executive Management Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract] Performance obligations [axis] Performance obligations [axis] Countries outside United States and Japan Countries Outside United States and Japan [Member] Represents the information pertaining to countries outside United States and Japan. Total liabilities Total liabilities Liabilities Selling, general and administrative expenses Staff Costs Included In Selling, General and Administrative Expenses The amount of staff cost included in selling, general and administrative expenses. Government Grants Description of accounting policy for government grants [text block] Number of shares authorized for repurchase (in shares) Number Of Shares Authorized To Be Repurchased The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan. Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] Corporate tax payable Current tax liabilities, current Statement of profit or loss and other comprehensive income [abstract] Discount rate applied to cash flow projections Discount rate applied to cash flow projections Exchange rate adjustment Increase (decrease) through net exchange differences, property, plant and equipment Retrospective application and retrospective restatement [axis] Retrospective application and retrospective restatement [axis] Lease liabilities Lease liabilities [member] Contractually entitled to receive amount in additional development, regulatory and sales milestone payments Receivable Amount Related to Additional Development, Regulatory and Sales Milestone Payments Represents the contractually entitled to receive an aggregate payment, related to additional development, regulatory and sales milestone payments for all programs. Current tax on profit Current tax expense (income) Term Loan B (Secured) Term Loan B (Secured) [Member] Term Loan B (Secured) Schedule of staff costs Disclosure Of Staff Cost [Table Text Block] Disclosure of staff cost. Triple A-rating Triple A-Rating [Member] This member stands for Triple A-rating. New Accounting Policies and Disclosure For 2025 Disclosure of initial application of standards or interpretations [text block] Proportion of share capital % Proportion Of Share Capital [Abstract] No definition available. Top of range Top of range [member] Genmab B.V. Genmab B.v. [Member] This member stands for Genmab B.V. Research and development expenses Research and development expense Scenario [Axis] Scenario [Axis] Contingent commitments Contingent Commitments, Amount The contingent commitments relates to license and collaboration agreements. 2028 Later than three years and not later than four years [member] Payment terms Payment Terms The description of initial payment terms range. TEPEZZA TEPEZZA [Member] This member stands for TEPEZZA. Collaborative Arrangement and Arrangement Other Than Collaborative [Axis] Collaborative Arrangement and Arrangement Other Than Collaborative [Axis] Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. Interest and other financial income Interest And Other Financial Income The interest and other financial income. Inventories Description of accounting policy for measuring inventories [text block] Share repurchase, percentage of purchase price deviation from quoted price Share Repurchase, Percentage Of Purchase Price Deviation From Quoted Price Share Repurchase, Percentage Of Purchase Price Deviation From Quoted Price Summary of warrants activity Disclosure Of Warrants Activity [Table Text Block] Tabular disclosure of warrants activity. Non-current assets Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Reduction in share capital Reduction Of Issued Capital, At Cost Reduction Of Issued Capital, At Cost Borrowings by name [domain] Borrowings by name [domain] Currency risk Currency risk [member] Functional and Presentation Currency Change Description of accounting policy for functional currency [text block] Deferred tax liabilities Deferred tax liabilities Geographical [Axis] Geographical [Axis] Other comprehensive income Other comprehensive income Transfer into Level 3 Transfers out of Level 3 of fair value hierarchy, assets Treasury shares Treasury shares [member] Total identifiable net assets Identifiable assets acquired (liabilities assumed) Changes in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Schedule of remuneration to the Board of Directors Disclosure of Amounts Incurred by Entity for Provision of Key Management Personnel [Table Text Block] The tabular disclosure of amounts incurred by entity for provision of key management personnel . Interest expense on borrowings Interest expense on borrowings Title of 12(b) Security Title of 12(b) Security Number of CGU Number Of Cash Generated Units Number Of Cash Generated Units Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] Unsecured revolving credit facility term Debt Instrument, Term1 Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Bank borrowings, undiscounted cash flows Bank borrowings, undiscounted cash flows Share capital reduction (in shares) Reduction in share capital (in shares) Number of treasury shares cancelled (in shares) Number Of Treasury Shares Cancelled Number Of Treasury Shares Cancelled Employee notice period Employee Notice period The period for which employee service the notice for service. Losses related to receivables and the credit risk on receivables is limited Amount By Which Receivables Related Credit Derivatives Or Similar Instruments Mitigate Maximum Exposure To Credit Risk The amount by which credit derivatives or similar instruments related to receivables mitigate maximum exposure to credit risk. [Refer: Loans and receivables. Upfront fee paid Collaborations Agreement, Upfront Fee Paid The amount of upfront fee payment made under an collaboration agreement. Excess Cash Flow Prepayment Scenario [Axis] Excess Cash Flow Prepayment Scenario [Axis] Excess Cash Flow Prepayment Scenario Receivables Non-current receivables Trade and other non-current receivables Attribution of expenses by nature to their function [domain] Attribution of expenses by nature to their function [domain] Treasury Shares Description of accounting policy for treasury shares [text block] Risk-free interest rate Weighted Average Risk Free Interest Rate, Warrants Granted Weighted average risk free interest rate of warrants granted. Subsidiaries [domain] Subsidiaries [domain] Debt issuance costs paid Repayments of borrowings, classified as financing activities Number of FTE at year-end Number Of Full Time Employment Number of FTE at year-end. Borrowings by name [axis] Borrowings by name [axis] Change in operating assets and liabilities Ifrs Increase (Decrease) in Operating Capital [Abstract] NA Schedule of other payables Disclosure of trade and other payables [text block] Defined Contribution Plans Key management personnel compensation, other long-term employee benefits Staff costs are included in the income statement as follows: Staff Costs Are Included In Income Statement As Follows [Abstract] No definition. BioNTech BioNTech [Member] This member stands for collaboration arrangements with BioNTech. Borrowings Description of accounting policy for borrowings [text block] Allowances at year end Accumulated impairment [member] Loss on marketable securities Loss on marketable securities Losses on Marketable Securities The losses on marketable securities. Schedule of changes in share capital Disclosure of reserves within equity [text block] Schedule of detailed information about property, plant and equipment Disclosure of detailed information about property, plant and equipment [text block] Other investments Other Investment [Member] Represents information pertaining to other investments. Classes of intangible assets and goodwill [domain] Classes of intangible assets and goodwill [domain] Interest Borrowings, interest rate Net cash (used in) investing activities Investing activities Cash flows from (used in) investing activities Number of future differentiated antibody for cancer to be discover Number of Future Differentiated Antibody Therapeutics for Cancer Number of future differentiated antibody therapeutics for cancer to be discover under research collaboration. Commercial paper Commercial Paper. [Member] Unsecured promissory note (generally negotiable) that provides institutions with short-term funds. Kesimpta Kesimpta [Member] This member stands for Kesimpta. Proportion of share capital on purchase of treasury shares (in %) Percentage Of Share Capital On Purchase Of Treasury Shares Percentage of proportion of share capital on purchase of treasury shares. Selling, general and administrative expenses Selling, General And Administrative Expenses of Acquiree The amount of selling, general and administrative expenses of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] DARZALEX DARZALEX [Member] This member stands for DARZALEX. Non-convertible debt financing Non-Convertible Debt Financing [Member] Non-Convertible Debt Financing Total Employee benefits expense Genmab US, Inc. Genmab Us Inc. [Member] This member stands for Genmab US, Inc. Amortization for the year Amortisation, intangible assets other than goodwill Increase in interest expense Increase (Decrease) In Interest Expense Increase In Interest Expense Financial instruments Description of accounting policy for financial instruments [text block] Total current assets Current assets Number of product concepts Number Of Product Concepts To Be Identified To Research And Development Number Of Product Concepts To Be Identified To Research And Development Recognised in Profit or Loss Deferred tax expense (income) recognised in profit or loss Total Expenses Of Acquiree The amount of expenses of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. Excess cash flow, threshold, prepayment percentage Borrowings, Excess Cash Flow, Threshold, Prepayment Percentage Borrowings, Excess Cash Flow, Threshold, Prepayment Percentage Types of risks [axis] Types of risks [axis] Anders Gersel Pedersen Anders Gersel Pedersen [Member] Represents information pertaining to Anders Gersel Pedersen. Result for the Year Results For Year [Text Block] The entire disclosure for results for the year. Summary of warrant terms Disclosure Of Warrant Terms [Table Text Block] Disclosure Of Warrant Terms Depreciation for the year Depreciation, property, plant and equipment Marketable securities bought Purchase of investments other than investments accounted for using equity method Share capital (USD million) Share capital [Abstract] No definition available. Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] Financial assets measured at amortized cost Financial assets at amortised cost, category [member] Par value per share (in DKK per share) Nominal amount (in DKK per share) Par value per share 3 – 5 years Later than three years and not later than five years [member] Schedule of property, plant and equipment Disclosure of property, plant and equipment [text block] Schedule of future minimum payments under our leases Disclosure of maturity analysis of operating lease payments [text block] Deferred tax assets Net deferred tax assets Warrants available for issue (in shares) Number Of Warrants Remaining Available For Issue Number of warrants remaining available for issue. Amendment Flag Amendment Flag Components of equity [domain] Components of equity [domain] Deirdre P. Connelly Deirdre P. Connelly [Member] Represents information pertaining to Deirdre P. Connelly. Changes in deferred tax liability (asset) [abstract] Changes in deferred tax liability (asset) [abstract] Staff costs Description of accounting policy for employee benefits [text block] Settled (in shares) Number Of Instruments Other Equity Instruments, Warrants, Settled Number of warrants settled. Royalty percentage for non-cancer treatment Collaborations Agreement, Non Cancer Treatment, Royalty Percentage On World Wide Net Sales The percentage of royalties of worldwide net sales ofatumumab for the treatment of non-cancer under the agreement. Exercised (in shares) Exercise of warrants (in shares) Number Of Warrants Exercised During Period The number of warrants exercised during period. Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Number of treasury shares acquired (in shares) Number Of Treasury Shares Acquired Number Of Treasury Shares Acquired Forfeited (in shares) Number Of Warrants Cancelled Number of warrants cancelled. Range [domain] Range [domain] Classes of contingent liabilities [axis] Classes of contingent liabilities [axis] Martine van Vugt Martine van Vugt [Member] Represents information pertaining to Martine van Vugt. Scenario [Domain] Scenario [Domain] Pfizer Pfizer [Member] This member stands for Pfizer. Total fair value of RSU granted (in DKK) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. Liabilities Liabilities, Temporary Difference [Member] Liabilities, Temporary Difference Previously stated Previously stated [member] Exercise of warrants Increase (decrease) through exercise of warrants, equity Schedule of corporate and deferred tax Disclosure Of Corporate And Deferred Tax [Table Text Block] Tabular disclosure for corporate and deferred Tax. Other Disclosures Other Disclosure [Text Block] The entire information of other disclosures. Annual Cash Bonus Key Management Personnel Compensation, Annual Cash Bonus The amount of compensation to key management personnel in the form of cash bonus. Clinical Development and Commercial Success Across all Three Programs Clinical Development and Commercial Success Across all Three Programs [Member] Represents the information pertaining to success of clinical development and commercial success across all the three programs. Address Type [Domain] Address Type [Domain] Notional amount Notional amount Notional amount Lease liabilities Current Current lease liabilities Currency [Axis] Currency [Axis] Tiered royalty percentage Collaborations Agreement, Tiered Royalty Percentage The percentage of tiered royalty under the collaboration agreement. Diluted net profit per share (in dollars per share) Earnings per share - diluted (in DKK and US Dollars per share) Diluted earnings (loss) per share Maturity [domain] Maturity [domain] Schedule of activities of the subsidiary Disclosure of interests in subsidiaries [text block] Categories of financial liabilities [axis] Categories of financial liabilities [axis] Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Janssen (DuoBody) Agreement with Janssen (DuoBody) [Member] Represents the information pertaining to agreement with Janssen (DuoBody). Effective Tax Rate Average effective tax rate At fair value At fair value [member] Warrants available for reissue (in shares) Number Of Warrants Remaining Available For Reissue Number of warrants remaining available for reissue. Disclosure Of Detailed Information About Changes in Presentation Currency [Line Items] Disclosure Of Detailed Information About Changes in Presentation Currency [Line Items] Disclosure Of Detailed Information About Changes in Presentation Currency Disclosure of Reconciliation of Financial Assets [Roll Forward] Disclosure of Reconciliation of Financial Assets [Roll Forward] Disclosure of Reconciliation of Financial Assets Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Investment in intangible assets Purchase of intangible assets, classified as investing activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Financial Income and Expenses Description of accounting policy for finance income and costs [text block]